pharma news today glp-1 obesity drugs today Roche was among the first pharmaceutical companies to research in the glucagon-like peptide-1 (GLP-1) class but abandoned the field after late-stage flops just before the latest boom began.⁠ ⁠ Having Growth, Volume, Price: The Skinny

In addition, Asia Pacific is projected to increase in the global GLP-1 agonists market because diabetes and other linked illnesses are becoming more common

Everything is online, the process starts with a 2-minute quiz , and you could have medication heading to your door without ever setting foot in a clinic

Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs

Oral GLP-1 Approaches Commercial Inflection by 2028 GLP-1 Weight Loss Drug Market Revenue Share, CAGR, and Primary Drivers by Route 2026 Subcutaneous injectable administration commands 81.7% GLP-1 market revenue share in 2026 as the weekly autoinjector format delivers clinical efficacy, dose consistency, and patient convenience superior to daily injectable alternatives

In addition, mice treated with any of the three low doses of GLP1/E displayed improved glucose handling and basal glucose levels, with higher responses in mice treated with 10 and 25 nmol/kg doses (Fig